Gavi HPV Programs: Application to Implementation

被引:47
作者
Hanson, Celina M. [1 ]
Eckert, Linda [2 ]
Bloem, Paul [3 ]
Cernuschi, Tania [3 ]
机构
[1] Gavi Vaccine Alliance Secretariat, CH-1211 Geneva 10, Switzerland
[2] Univ Washington, Dept Obstet & Gynecol, Box 359865,325 9th Ave, Seattle, WA 98104 USA
[3] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva 27, Switzerland
关键词
HPV; vaccination; cervical cancer;
D O I
10.3390/vaccines3020408
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings.
引用
收藏
页码:408 / 419
页数:12
相关论文
共 28 条
[1]   Gardasil: from bench, to bedside, to blunder [J].
Bach, Peter B. .
LANCET, 2010, 375 (9719) :963-964
[2]  
Bosch FX, 2013, VACCINE, V31, pF1, DOI [10.1016/j.vaccine.2013.10.001, 10.1016/j.vaccine.2013.07.026, 10.1016/j.vaccine.2013.10.003]
[3]   Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study [J].
Brabin, Loretta ;
Roberts, Stephen A. ;
Stretch, Rebecca ;
Baxter, David ;
Chambers, Gloria ;
Kitchener, Henry ;
McCann, Rosemary .
BRITISH MEDICAL JOURNAL, 2008, 336 (7652) :1056-1058
[4]   Effective Health Interventions for Adolescents That Could Be Integrated With Human Papillomavirus Vaccination Programs [J].
Broutet, Nathalie ;
Lehnertz, Nicholas ;
Mehl, Garrett ;
Camacho, Alma Virginia ;
Bloem, Paul ;
Chandra-Mouli, Venkatraman ;
Ferguson, Jane ;
Dick, Bruce .
JOURNAL OF ADOLESCENT HEALTH, 2013, 53 (01) :6-13
[5]   Human papillomavirus and cervical cancer [J].
Burd, EM .
CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) :1-+
[6]  
Dorell Christina, 2011, Morbidity and Mortality Weekly Report, V60, P1117
[7]  
Dorleans F., CURRENT STATE INTRO
[8]  
Goulds S., 2013, DOUBLE JEOPARDY ADOL
[9]  
Govan Vandana A, 2008, Ther Clin Risk Manag, V4, P65
[10]   Effective Nonvaccine Interventions to Be Considered Alongside Human Papilloma Virus Vaccine Delivery [J].
Hindin, Michelle J. ;
Bloem, Paul ;
Ferguson, Jane .
JOURNAL OF ADOLESCENT HEALTH, 2015, 56 (01) :10-18